Corporate Profile

CalciMedica is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of CRAC channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies.

Learn More

Stock Information

Minimum 15 minutes delayed. Source:

Press Releases

30 Oct 24

CalciMedica Announces Pricing of Public Offering of Common Stock

LA JOLLA, Calif. , Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and
30 Oct 24

CalciMedica Announces Proposed Public Offering of Common Stock

LA JOLLA, Calif. , Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. (" CalciMedica " or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and
30 Oct 24

CalciMedica to Present Late-Breaking Positive Data, Including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP) at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting

Statistically significant 100% reduction (p = 0.0027) in new-onset severe respiratory failure and 64.2% reduction (p = 0.0476) in new-onset persistent respiratory failure in combined high and medium dose Auxora patients versus combined low dose Auxora and placebo patients Statistically significant
28 Oct 24

CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Conference call and webcast to be held Wednesday, October 30, 2024 at 12 p.m. ET / 9 a.m. PT LA JOLLA, Calif. , Oct. 28, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium